https://m2.mtmt.hu/ hun 2026-10-25 02:06 JournalArticle 36202274 ADMIN_APPROVED true * Megosztott szerzőség 0 false 2026-10-21T10:28:47.238+0000 2026-05-18T14:41:46.967+0000 2025-06-21T10:51:22.770+0000 true 10058020 Fekete Mónika /api/author/10058020 Author Fekete Mónika (Népegészségtan) true 10058020 2026-10-21T10:25:07.444+0000 2026-04-01T11:49:49.242+0000 true 10093553 Fi Tamás /api/admin/10093553 Admin Fi Tamás (SE_AOK_Nepegeszsegtan_Admin5_FT, admin) true true false true 24 24 /api/publicationtype/24 PublicationType Folyóiratcikk 1 true 24 JournalArticle true 10000059 Article true 24 24 /api/publicationtype/24 PublicationType Folyóiratcikk 1 true 24 JournalArticle /api/subtype/10000059 Szakcikk SubType Szakcikk (Folyóiratcikk) 101 true 10000059 true 1 /api/category/1 Category Tudományos true 1 Ungvari, Zoltan true true /api/journal/10071822 REVIEWED GEROSCIENCE: OFFICIAL JOURNAL OF THE AMERICAN AGING ASSOCIATION (AGE) 2509-2715 2509-2723 true false 10071822 false 10071822 true 2509-2715 2509-2723 Journal FOREIGN 48 1 1345 1356 1345 12 2026 Lung cancer is a leading cause of cancer-related mortality worldwide. As an age-related disease, its pathogenesis is shaped by several molecular hallmarks of aging, including impaired DNA repair and diminished stress resilience. The transcription factor NRF2 (nuclear factor erythroid 2–related factor 2) is a master regulator of oxidative stress defense and cellular survival. While NRF2 activation is protective in aging tissues, it may also be exploited by cancer cells to promote tumor progression and therapy resistance. This study aims to evaluate whether NRF2 pathway activation predicts clinical outcomes in lung cancer, with potential implications for the use of NRF2-inducing compounds. We analyzed transcriptomic and survival data from 2167 lung cancer patients using the KM Plotter database. A validated 14-gene NRF2 activation signature was used to stratify tumors by NRF2 pathway activity. Associations with overall survival (OS), first progression (FP), and post-progression survival (PPS) were assessed using Cox regression models and Kaplan–Meier analysis. High NRF2 signature expression was significantly associated with poorer OS (HR = 1.59, p = 1.3E−9), FP (HR = 1.61, p = 2.6E−5), and PPS (HR = 1.6, p = 0.002). The negative prognostic effect was most pronounced in patients with adenocarcinoma, node-negative disease, and in female patients. These findings highlight the dual role of NRF2 in promoting stress resilience and enabling cancer cell survival. NRF2 activation is a predictor of poor clinical outcomes in lung cancer. Given the widespread use of NRF2-inducing compounds such as resveratrol and sulforaphane, these findings raise important concerns about their safety in individuals at risk for or living with cancer. Our results underscore the importance of context-specific evaluation of NRF2-targeted interventions and caution against the indiscriminate use of NRF2-activating agents in aging populations, particularly in individuals at risk for lung cancer. Funding 2054340 /api/funding/2054340 (FK147194) false true Funding 2054341 /api/funding/2054341 Nemzeti Gyógyszerkutatási és Fejlesztési Laboratórium (PharmaLab)(RRF-2.3.1-21-2022-00015) Támogató: NKFIH false true Funding 2054342 /api/funding/2054342 (TKP2021-NKTA-47) false true Funding 2054343 /api/funding/2054343 Nemzeti Kardiovaszkuláris Laboratórium(RRF-2.3.1-21-2022-00003) Támogató: NKFIH false true Funding 2054344 /api/funding/2054344 (TKCS-2021/32) false true Funding 2054345 /api/funding/2054345 (EKÖP-2024-9) false true true 2025 true true true false true false GOLD 2026-10-21 true https://doi.org/10.1007/s11357-025-01736-0 6 0 6 4 1 6 4 2 1 3 3 3 3 4 2 0 6 4 6 4 0 7 7 Folyóiratcikk Journal Article 24 3 Könyvrészlet Chapter in Book 25 3 Könyv Book 23 0 Egyéb konferenciaközlemény Conference paper 31 0 Egyéb konferenciakötet Conference proceedings 32 0 Oltalmi formák Protection forms 26 0 Disszertáció Thesis 28 0 Egyéb Miscellaneous 29 0 Alkotás Achievement 22 0 Kutatási adat Research data 33 0 Folyóiratcikk Journal Article 24 0 0 0 Könyvrészlet Chapter in Book 25 0 0 0 Könyv Book 23 0 0 0 Egyéb konferenciaközlemény Conference paper 31 0 0 0 Egyéb konferenciakötet Conference proceedings 32 0 0 0 Oltalmi formák Protection forms 26 0 0 0 Disszertáció Thesis 28 0 0 0 Egyéb Miscellaneous 29 0 0 0 Alkotás Achievement 22 0 0 0 Kutatási adat Research data 33 0 0 0 2025 0 2 1 2 1 2026 0 4 3 4 3 D1 false false false false 2025-09-19T10:51:29.336+0000 Biofizikai Intézet (PTE / ÁOK); Bioinformatika Tanszék (SE / AOK / I); Doktori Iskola (SE); Megelőző Orvostani és Népegészségtani Intézet (SE / AOK / I); Onkológiai Biomarker Kutatócsoport (Lendület) (HRN TTK / MÉI) 7 47 5 8 0 true Language 10002 /api/language/10002 Angol Angol English true 2 true PersonAuthorship 126970089 /api/authorship/126970089 Ungvari, Zoltan [Ungvári, Zoltán István (Orvostudomány, me...), szerző] Megelőző Orvostani és Népegészségtani Intézet (SE / AOK / I) 1 0.125 true false false Author 10043602 /api/author/10043602 Ungvári Zoltán István (Orvostudomány, megelőző orvostan, népegészségtan, kórélettan, gerontológia) Ungvári Zoltán István true 10043602 true Ungvari Zoltan true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 126970090 /api/authorship/126970090 Menyhart, Otília* [Menyhárt, Otília (Onkológia), szerző] Bioinformatika Tanszék (SE / AOK / I); Onkológiai Biomarker Kutatócsoport (Lendület) (HRN TTK / MÉI) 2 0.125 true false false Author 10045338 /api/author/10045338 Menyhárt Otília (Onkológia) Menyhárt Otília true 10045338 true Menyhart Otília true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 126970091 /api/authorship/126970091 Lehoczki, Andrea* ✉ [Lehoczki, Andrea Marianna (hematológia, belg...), szerző] Megelőző Orvostani és Népegészségtani Intézet (SE / AOK / I); Doktori Iskola (SE) 3 0.125 true false true Author 10089009 /api/author/10089009 Lehoczki Andrea Marianna (hematológia, belgyógyászat) Lehoczki Andrea Marianna true true Lehoczki Andrea true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 126970092 /api/authorship/126970092 Fekete, Monika [Fekete, Mónika (Népegészségtan), szerző] Megelőző Orvostani és Népegészségtani Intézet (SE / AOK / I) 4 0.125 false false false Author 10058020 /api/author/10058020 Fekete Mónika (Népegészségtan) Fekete Mónika true 10058020 true Fekete Monika true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 126970093 /api/authorship/126970093 Fazekas-Pongor, Vince [Fazekas-Pongor, Vince (népegészségtan), szerző] Megelőző Orvostani és Népegészségtani Intézet (SE / AOK / I) 5 0.125 false false false Author 10035785 /api/author/10035785 Fazekas-Pongor Vince (népegészségtan) Fazekas-Pongor Vince true 10035785 true Fazekas-Pongor Vince true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 126970094 /api/authorship/126970094 Ocana, Alberto 6 0.125 false false false Ocana Alberto true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 126970095 /api/authorship/126970095 Varga, Peter [Varga, Péter (foglalkozás-orvostan), szerző] Megelőző Orvostani és Népegészségtani Intézet (SE / AOK / I) 7 0.125 false false false Author 10081446 /api/author/10081446 Varga Péter (foglalkozás-orvostan) Varga Péter true true Varga Peter true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 126970096 /api/authorship/126970096 Győrffy, Balázs [Győrffy, Balázs (Onkológia), szerző] Onkológiai Biomarker Kutatócsoport (Lendület) (HRN TTK / MÉI); Bioinformatika Tanszék (SE / AOK / I); Biofizikai Intézet (PTE / ÁOK) 8 0.125 false true false Author 10000109 /api/author/10000109 Győrffy Balázs (Onkológia) Győrffy Balázs true 10000109 true Győrffy Balázs true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PublicationIdentifier 29507432 /api/publicationidentifier/29507432 DOI: 10.1007/s11357-025-01736-0 PlainSource 6 /api/publicationsource/6 DOI PublicationSourceType 10001 /api/publicationsourcetype/10001 DOI true true true DOI DOI https://doi.org/@@@ true true 6 true GOLD true IDENTICAL 10.1007/s11357-025-01736-0 https://doi.org/10.1007/s11357-025-01736-0 false true PublicationIdentifier 29511458 /api/publicationidentifier/29511458 WoS: 001511729300001 PlainSource 1 /api/publicationsource/1 WoS PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true WoS WoS https://www.webofscience.com/wos/woscc/full-record/@@@ true true 1 true IDENTICAL 001511729300001 https://www.webofscience.com/wos/woscc/full-record/001511729300001 true true PublicationIdentifier 33047553 /api/publicationidentifier/33047553 REAL: 246670 SwordSource 36 /api/publicationsource/36 REAL PublicationSourceType 10007 /api/publicationsourcetype/10007 Repozitórium true true true REAL REAL https://real.mtak.hu/@@@ true true 36 true GOLD true 246670 https://real.mtak.hu/246670 false true PublicationIdentifier 29539358 /api/publicationidentifier/29539358 Scopus: 105008382211 PlainSource 3 /api/publicationsource/3 Scopus PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true Scopus Scopus http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-@@@ true true 3 true IDENTICAL 105008382211 http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-105008382211 false true PublicationIdentifier 29511538 /api/publicationidentifier/29511538 PubMed: 40537696 PlainSource 17 /api/publicationsource/17 PubMed PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true PubMed PubMed http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=@@@&dopt=Abstract true true 17 true IDENTICAL 40537696 http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=40537696&dopt=Abstract false true PublicationIdentifier 31297320 /api/publicationidentifier/31297320 Egyéb URL: https://www.scopus.com/inward/record.uri?eid=2-s2.0-105008382211&doi=10.1007%2Fs11357-025-01736-0&partnerID=40&md5=0634bfaa6d6206f66167818ffa7c889c PlainSource 40 /api/publicationsource/40 Egyéb URL PublicationSourceType 10006 /api/publicationsourcetype/10006 Link true true true Egyéb URL Other URL @@@ true true 40 true NONE IDENTICAL https://www.scopus.com/inward/record.uri?eid=2-s2.0-105008382211&doi=10.1007%2Fs11357-025-01736-0&partnerID=40&md5=0634bfaa6d6206f66167818ffa7c889c https://www.scopus.com/inward/record.uri?eid=2-s2.0-105008382211&doi=10.1007%2Fs11357-025-01736-0&partnerID=40&md5=0634bfaa6d6206f66167818ffa7c889c false true PublicationIdentifier 32201276 /api/publicationidentifier/32201276 Egyéb URL: https://www.scopus.com/pages/publications/105008382211?origin=resultslist PlainSource 40 /api/publicationsource/40 Egyéb URL PublicationSourceType 10006 /api/publicationsourcetype/10006 Link true true true Egyéb URL Other URL @@@ true true 40 true NONE IDENTICAL https://www.scopus.com/pages/publications/105008382211?origin=resultslist https://www.scopus.com/pages/publications/105008382211?origin=resultslist false true SjrRating 11734232 /api/sjrrating/11734232 sjr:D1 (2026) Scopus - Veterinary (miscellaneous) GEROSCIENCE: OFFICIAL JOURNAL OF THE AMERICAN AGING ASSOCIATION (AGE) 2509-2715 2509-2723 2 0.0 journal RatingType 10002 /api/ratingtype/10002 sjr sjr true true ClassificationExternal 3401 /api/classificationexternal/3401 Scopus - Veterinary (miscellaneous) true 3401 true D1 FROM_LAST_YEAR true true Reference 66478146 /api/reference/66478146 1. Barta JA, Powell CA, Wisnivesky JP. Global epidemiology of lung cancer. Ann Glob Health. 2019;85 https://doi.org/10.5334/aogh.2419., DOI: 10.5334/aogh.2419 1 10.5334/aogh.2419 false true Reference 66478147 /api/reference/66478147 2. Satoh H, Okuma Y, Shinno Y, Masuda K, Matsumoto Y, Yoshida T, Goto Y, Horinouchi H, Yamamoto N, Ohe Y. Evolving treatments and prognosis in Stage IV non-small cell lung cancer: 20 years of progress of novel therapies. Lung Cancer. 2025;202:108453. https://doi.org/10.1016/j.lungcan.2025.108453., DOI: 10.1016/j.lungcan.2025.108453 2 10.1016/j.lungcan.2025.108453 false true Reference 66478148 /api/reference/66478148 3. Jung HA, Lee DH, Lim SM, Yu H, Yoon S, Kim D, Kim KP, Jeong H, Doh H, Lim S, Kim J, Zhao X, Horsburgh D, Patel D, Kim JA, Toh KC. Epidemiology and outcomes of non-small cell lung cancer in South Korea. JAMA Netw Open. 2024;7:e2355331. https://doi.org/10.1001/jamanetworkopen.2023.55331., DOI: 10.1001/jamanetworkopen.2023.55331 3 10.1001/jamanetworkopen.2023.55331 false true Reference 66478149 /api/reference/66478149 4. Owonikoko TK, Ragin CC, Belani CP, Oton AB, Gooding WE, Taioli E, Ramalingam SS. Lung cancer in elderly patients: an analysis of the surveillance, epidemiology, and end results database. J Clin Oncol. 2007;25:5570–7. https://doi.org/10.1200/JCO.2007.12.5435., DOI: 10.1200/JCO.2007.12.5435 4 10.1200/JCO.2007.12.5435 false true Reference 66478150 /api/reference/66478150 5. Lopez-Otin C, Pietrocola F, Roiz-Valle D, Galluzzi L, Kroemer G. Meta-hallmarks of aging and cancer. Cell Metab. 2023;35:12–35. https://doi.org/10.1016/j.cmet.2022.11.001., DOI: 10.1016/j.cmet.2022.11.001 5 10.1016/j.cmet.2022.11.001 false true Reference 66478151 /api/reference/66478151 6. Cordoba-Lanus E, Montuenga LM, Dominguez-de-Barros A, Oliva A, Mayato D, Remirez-Sanz A, Gonzalvo F, Celli B, Zulueta JJ, Casanova C. Oxidative damage and telomere length as markers of lung cancer development among chronic obstructive pulmonary disease (COPD) smokers. Antioxidants. 2024;13 https://doi.org/10.3390/antiox13020156., DOI: 10.3390/antiox13020156 6 10.3390/antiox13020156 false true Reference 66478152 /api/reference/66478152 7. Haston S, Gonzalez-Gualda E, Morsli S, Ge J, Reen V, Calderwood A, Moutsopoulos I, Panousopoulos L, Deletic P, Carreno G, Guiho R, Manshaei S, Gonzalez-Meljem JM, Lim HY, Simpson DJ, Birch J, Pallikonda HA, Chandra T, Macias D, et al. Clearance of senescent macrophages ameliorates tumorigenesis in KRAS-driven lung cancer. Cancer Cell. 2023;41:1242–1260e1246. https://doi.org/10.1016/j.ccell.2023.05.004., DOI: 10.1016/j.ccell.2023.05.004 7 10.1016/j.ccell.2023.05.004 false true Reference 66478153 /api/reference/66478153 8. Gao X, Yi L, Jiang C, Li S, Wang X, Yang B, Li W, Che N, Wang J, Zhang H, Zhang S. PCSK9 regulates the efficacy of immune checkpoint therapy in lung cancer. Front Immunol. 2023;14:1142428. https://doi.org/10.3389/fimmu.2023.1142428., DOI: 10.3389/fimmu.2023.1142428 8 10.3389/fimmu.2023.1142428 false true Reference 66478154 /api/reference/66478154 9. Fekete M, Major D, Feher A, Fazekas-Pongor V, Lehoczki A. Geroscience and pathology: a new frontier in understanding age-related diseases. Pathol Oncol Res. 2024; https://doi.org/10.3389/pore.2024.1611623., DOI: 10.3389/pore.2024.1611623 9 10.3389/pore.2024.1611623 false true Reference 66478155 /api/reference/66478155 10. Lewis KN, Mele J, Hornsby PJ, Buffenstein R. Stress resistance in the naked mole-rat: the bare essentials - a mini-review. Gerontology. 2012; https://doi.org/10.1159/000335966., DOI: 10.1159/000335966 10 10.1159/000335966 false true Reference 66478156 /api/reference/66478156 11. Miller RA. Cell stress and aging: new emphasis on multiplex resistance mechanisms. J Gerontol A Biol Sci Med Sci. 2009;64:179–82. https://doi.org/10.1093/gerona/gln072., DOI: 10.1093/gerona/gln072 11 10.1093/gerona/gln072 false true Reference 66478157 /api/reference/66478157 12. Harper JM, Salmon AB, Chang Y, Bonkowski M, Bartke A, Miller RA. Stress resistance and aging: influence of genes and nutrition. Mech Ageing Dev. 2006;127:687–94., DOI: 10.1016/j.mad.2006.04.002 12 10.1016/j.mad.2006.04.002 false true Reference 66478158 /api/reference/66478158 13. Lithgow GJ, Walker GA. Stress resistance as a determinate of C. elegans lifespan. Mech Ageing Dev. 2002;123:765–71., DOI: 10.1016/S0047-6374(01)00422-5 13 10.1016/S0047-6374(01)00422-5 false true Reference 66478159 /api/reference/66478159 14. Luo J, Solimini NL, Elledge SJ. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell. 2009;136:823–37. https://doi.org/10.1016/j.cell.2009.02.024., DOI: 10.1016/j.cell.2009.02.024 14 10.1016/j.cell.2009.02.024 false true Reference 66478160 /api/reference/66478160 15. Greenwood HE, Barber AR, Edwards RS, Tyrrell WE, George ME, Dos Santos SN, Baark F, Tanc M, Khalil E, Falzone A, Ward NP, DeBlasi JM, Torrente L, Soni PN, Pearce DR, Firth G, Smith LM, Vilhelmsson Timmermand O, Huebner A, et al. Imaging NRF2 activation in non-small cell lung cancer with positron emission tomography. Nat Commun. 2024;15:10484. https://doi.org/10.1038/s41467-024-54852-4., DOI: 10.1038/s41467-024-54852-4 15 10.1038/s41467-024-54852-4 false true Reference 66478161 /api/reference/66478161 16. Kansanen E, Kuosmanen SM, Leinonen H, Levonen AL. The Keap1-Nrf2 pathway: mechanisms of activation and dysregulation in cancer. Redox Biol. 2013;1:45–9. https://doi.org/10.1016/j.redox.2012.10.001., DOI: 10.1016/j.redox.2012.10.001 16 10.1016/j.redox.2012.10.001 false true Reference 66478162 /api/reference/66478162 17. van der Wijst MG, Brown R, Rots MG. Nrf2, the master redox switch: the Achilles' heel of ovarian cancer? Biochim Biophys Acta. 2014;1846:494–509. https://doi.org/10.1016/j.bbcan.2014.09.004., DOI: 10.1016/j.bbcan.2014.09.004 17 10.1016/j.bbcan.2014.09.004 false true Reference 66478163 /api/reference/66478163 18. Leinonen HM, Kansanen E, Polonen P, Heinaniemi M, Levonen AL. Role of the Keap1-Nrf2 pathway in cancer. Adv Cancer Res. 2014;122:281–320. https://doi.org/10.1016/B978-0-12-420117-0.00008-6., DOI: 10.1016/B978-0-12-420117-0.00008-6 18 10.1016/B978-0-12-420117-0.00008-6 false true Reference 66478164 /api/reference/66478164 19. Jaramillo MC, Zhang DD. The emerging role of the Nrf2-Keap1 signaling pathway in cancer. Genes Dev. 2013;27:2179–91. https://doi.org/10.1101/gad.225680.113., DOI: 10.1101/gad.225680.113 19 10.1101/gad.225680.113 false true Reference 66478165 /api/reference/66478165 20. Menegon S, Columbano A, Giordano S. The dual roles of NRF2 in cancer. Trends Mol Med. 2016;22:578–93. https://doi.org/10.1016/j.molmed.2016.05.002., DOI: 10.1016/j.molmed.2016.05.002 20 10.1016/j.molmed.2016.05.002 false true Reference 66478166 /api/reference/66478166 21. Leinonen HM, Kansanen E, Polonen P, Heinaniemi M, Levonen AL. Dysregulation of the Keap1-Nrf2 pathway in cancer. Biochem Soc Trans. 2015;43:645–9. https://doi.org/10.1042/BST20150048., DOI: 10.1042/BST20150048 21 10.1042/BST20150048 false true Reference 66478167 /api/reference/66478167 22. Furfaro AL, Traverso N, Domenicotti C, Piras S, Moretta L, Marinari UM, Pronzato MA, Nitti M. The Nrf2/HO-1 axis in cancer cell growth and chemoresistance. Oxid Med Cell Longev. 2016;2016:1958174. https://doi.org/10.1155/2016/1958174., DOI: 10.1155/2016/1958174 22 10.1155/2016/1958174 false true Reference 66478168 /api/reference/66478168 23. Milkovic L, Zarkovic N, Saso L. Controversy about pharmacological modulation of Nrf2 for cancer therapy. Redox Biol. 2017;12:727–32. https://doi.org/10.1016/j.redox.2017.04.013., DOI: 10.1016/j.redox.2017.04.013 23 10.1016/j.redox.2017.04.013 false true Reference 66478169 /api/reference/66478169 24. Rojo de la Vega M, Chapman E, Zhang DD. NRF2 and the hallmarks of cancer. Cancer Cell. 2018;34:21–43. https://doi.org/10.1016/j.ccell.2018.03.022., DOI: 10.1016/j.ccell.2018.03.022 24 10.1016/j.ccell.2018.03.022 false true Reference 66478170 /api/reference/66478170 25. Adinolfi S, Patinen T, Jawahar Deen A, Pitkanen S, Harkonen J, Kansanen E, Kublbeck J, Levonen AL. The KEAP1-NRF2 pathway: targets for therapy and role in cancer. Redox Biol. 2023;63:102726. https://doi.org/10.1016/j.redox.2023.102726., DOI: 10.1016/j.redox.2023.102726 25 10.1016/j.redox.2023.102726 false true Reference 66478171 /api/reference/66478171 26. Glorieux C, Enriquez C, Gonzalez C, Aguirre-Martinez G, Buc CP. The multifaceted roles of NRF2 in cancer: friend or foe? Antioxidants. 2024;13 https://doi.org/10.3390/antiox13010070., DOI: 10.3390/antiox13010070 26 10.3390/antiox13010070 false true Reference 66478172 /api/reference/66478172 27. Ramisetti SV, Patra T, Munirathnam V, Sainath JV, Veeraiyan D, Namani A. NRF2 signaling pathway in chemo/radio/immuno-therapy resistance of lung cancer: looking beyond the tip of the iceberg. Arch Bronconeumol. 2024;60(Suppl 2):S59–66. https://doi.org/10.1016/j.arbres.2024.06.021., DOI: 10.1016/j.arbres.2024.06.021 27 10.1016/j.arbres.2024.06.021 false true Reference 66478173 /api/reference/66478173 28. Gyorffy B. Transcriptome-level discovery of survival-associated biomarkers and therapy targets in non-small-cell lung cancer. Br J Pharmacol. 2024;181:362–74. https://doi.org/10.1111/bph.16257., DOI: 10.1111/bph.16257 28 10.1111/bph.16257 false true Reference 66478174 /api/reference/66478174 29. Gyorffy B, Molnar B, Lage H, Szallasi Z, Eklund AC. Evaluation of microarray preprocessing algorithms based on concordance with RT-PCR in clinical samples. PLoS One. 2009;4:e5645. https://doi.org/10.1371/journal.pone.0005645., DOI: 10.1371/journal.pone.0005645 29 10.1371/journal.pone.0005645 false true Reference 66478175 /api/reference/66478175 30. Gyorffy B. Discovery and ranking of the most robust prognostic biomarkers in serous ovarian cancer. Geroscience. 2023;45:1889–98. https://doi.org/10.1007/s11357-023-00742-4., DOI: 10.1007/s11357-023-00742-4 30 10.1007/s11357-023-00742-4 false true Reference 66478176 /api/reference/66478176 31. Gyorffy B. Survival analysis across the entire transcriptome identifies biomarkers with the highest prognostic power in breast cancer. Comput Struct Biotechnol J. 2021;19:4101–9. https://doi.org/10.1016/j.csbj.2021.07.014., DOI: 10.1016/j.csbj.2021.07.014 31 10.1016/j.csbj.2021.07.014 false true Reference 66478177 /api/reference/66478177 32. Luo G, Kumar H, Aldridge K, Rieger S, Han E, Jiang E, Chan ER, Soliman A, Mahdi H, Letterio JJ. A Core NRF2 gene set defined through comprehensive transcriptomic analysis predicts selective drug resistance and poor multicancer prognosis. Antioxid Redox Signal. 2024;41:1031–50. https://doi.org/10.1089/ars.2023.0409., DOI: 10.1089/ars.2023.0409 32 10.1089/ars.2023.0409 false true Reference 66478178 /api/reference/66478178 33. Lewis KN, Mele J, Hayes JD, Buffenstein R. Nrf2, a guardian of healthspan and gatekeeper of species longevity. Integr Comp Biol. 2010;50:829–43. https://doi.org/10.1093/icb/icq034., DOI: 10.1093/icb/icq034 33 10.1093/icb/icq034 false true Reference 66478179 /api/reference/66478179 34. Siswanto FM, Sakuma R, Oguro A, Imaoka S. Chlorogenic acid activates Nrf2/SKN-1 and prolongs the lifespan of Caenorhabditis elegans via the Akt-FOXO3/DAF16a-DDB1 pathway and activation of DAF16f. J Gerontol A Biol Sci Med Sci. 2022;77:1503–16. https://doi.org/10.1093/gerona/glac062., DOI: 10.1093/gerona/glac062 34 10.1093/gerona/glac062 false true Reference 66478180 /api/reference/66478180 35. Tullet JMA, Green JW, Au C, Benedetto A, Thompson MA, Clark E, Gilliat AF, Young A, Schmeisser K, Gems D. The SKN-1/Nrf2 transcription factor can protect against oxidative stress and increase lifespan in C. elegans by distinct mechanisms. Aging Cell. 2017;16:1191–4. https://doi.org/10.1111/acel.12627., DOI: 10.1111/acel.12627 35 10.1111/acel.12627 false true Reference 66478181 /api/reference/66478181 36. Raynes R, Juarez C, Pomatto LC, Sieburth D, Davies KJ. Aging and SKN-1-dependent loss of 20S proteasome adaptation to oxidative stress in C. elegans. J Gerontol A Biol Sci Med Sci. 2017;72:143–51. https://doi.org/10.1093/gerona/glw093., DOI: 10.1093/gerona/glw093 36 10.1093/gerona/glw093 false true Reference 66478182 /api/reference/66478182 37. Pickering AM, Staab TA, Tower J, Sieburth DS, Davies KJ. A conserved role for the 20S proteasome and Nrf2 transcription factor in oxidative-stress adaptation in mammals, C. elegans and D. melanogaster. J Exp Biol. 2012; https://doi.org/10.1242/jeb.074757., DOI: 10.1242/jeb.074757 37 10.1242/jeb.074757 false true Reference 66478183 /api/reference/66478183 38. Przybysz AJ, Choe KP, Roberts LJ, Strange K. Increased age reduces DAF-16 and SKN-1 signaling and the hormetic response of Caenorhabditis elegans to the xenobiotic juglone. Mech Ageing Dev. 2009;130:357–69. https://doi.org/10.1016/j.mad.2009.02.004., DOI: 10.1016/j.mad.2009.02.004 38 10.1016/j.mad.2009.02.004 false true Reference 66478184 /api/reference/66478184 39. Park SK, Tedesco PM, Johnson TE. Oxidative stress and longevity in Caenorhabditis elegans as mediated by SKN-1. Aging Cell. 2009;8:258–69. https://doi.org/10.1111/j.1474-9726.2009.00473.x., DOI: 10.1111/j.1474-9726.2009.00473.x 39 10.1111/j.1474-9726.2009.00473.x false true Reference 66478185 /api/reference/66478185 40. Tullet JM, Hertweck M, An JH, Baker J, Hwang JY, Liu S, Oliveira RP, Baumeister R, Blackwell TK. Direct inhibition of the longevity-promoting factor SKN-1 by insulin-like signaling in C. elegans. Cell. 2008;132:1025–38. https://doi.org/10.1016/j.cell.2008.01.030., DOI: 10.1016/j.cell.2008.01.030 40 10.1016/j.cell.2008.01.030 false true Reference 66478186 /api/reference/66478186 41. Sekhar KR, Freeman ML. Nrf2 promotes survival following exposure to ionizing radiation. Free Radic Biol Med. 2015;88:268–74. https://doi.org/10.1016/j.freeradbiomed.2015.04.035., DOI: 10.1016/j.freeradbiomed.2015.04.035 41 10.1016/j.freeradbiomed.2015.04.035 false true Reference 66478187 /api/reference/66478187 42. Kovac S, Angelova PR, Holmstrom KM, Zhang Y, Dinkova-Kostova AT, Abramov AY. Nrf2 regulates ROS production by mitochondria and NADPH oxidase. Biochim Biophys Acta. 2015;1850:794–801. https://doi.org/10.1016/j.bbagen.2014.11.021., DOI: 10.1016/j.bbagen.2014.11.021 42 10.1016/j.bbagen.2014.11.021 false true Reference 66478188 /api/reference/66478188 43. Jayakumar S, Pal D, Sandur SK. Nrf2 facilitates repair of radiation induced DNA damage through homologous recombination repair pathway in a ROS independent manner in cancer cells. Mutat Res. 2015;779:33–45. https://doi.org/10.1016/j.mrfmmm.2015.06.007., DOI: 10.1016/j.mrfmmm.2015.06.007 43 10.1016/j.mrfmmm.2015.06.007 false true Reference 66478189 /api/reference/66478189 44. Pomatto LCD, Dill T, Carboneau B, Levan S, Kato J, Mercken EM, Pearson KJ, Bernier M, de Cabo R. Deletion of Nrf2 shortens lifespan in C57BL6/J male mice but does not alter the health and survival benefits of caloric restriction. Free Radic Biol Med. 2020;152:650–8. https://doi.org/10.1016/j.freeradbiomed.2020.01.005., DOI: 10.1016/j.freeradbiomed.2020.01.005 44 10.1016/j.freeradbiomed.2020.01.005 false true Reference 66478190 /api/reference/66478190 45. Strong R, Miller RA, Antebi A, Astle CM, Bogue M, Denzel MS, Fernandez E, Flurkey K, Hamilton KL, Lamming DW, Javors MA, de Magalhaes JP, Martinez PA, McCord JM, Miller BF, Muller M, Nelson JF, Ndukum J, Rainger GE, et al. Longer lifespan in male mice treated with a weakly estrogenic agonist, an antioxidant, an alpha-glucosidase inhibitor or a Nrf2-inducer. Aging Cell. 2016;15:872–84. https://doi.org/10.1111/acel.12496., DOI: 10.1111/acel.12496 45 10.1111/acel.12496 false true Reference 66478191 /api/reference/66478191 46. Leiser SF, Miller RA. Nrf2 signaling, a mechanism for cellular stress resistance in long-lived mice. Mol Cell Biol. 2010;30:871–84. https://doi.org/10.1128/MCB.01145-09., DOI: 10.1128/MCB.01145-09 46 10.1128/MCB.01145-09 false true Reference 66478192 /api/reference/66478192 47. Pearson KJ, Lewis KN, Price NL, Chang JW, Perez E, Cascajo MV, Tamashiro KL, Poosala S, Csiszar A, Ungvari Z, Kensler TW, Yamamoto M, Egan JM, Longo DL, Ingram DK, Navas P, de Cabo R. Nrf2 mediates cancer protection but not prolongevity induced by caloric restriction. Proc Natl Acad Sci U S A. 2008;105:2325–30., DOI: 10.1073/pnas.0712162105 47 10.1073/pnas.0712162105 false true Reference 66478193 /api/reference/66478193 48. Martin-Montalvo A, Villalba JM, Navas P, de Cabo R. NRF2, cancer and calorie restriction. Oncogene. 2011;30:505–20. https://doi.org/10.1038/onc.2010.492., DOI: 10.1038/onc.2010.492 48 10.1038/onc.2010.492 false true Reference 66478194 /api/reference/66478194 49. Becks L, Prince M, Burson H, Christophe C, Broadway M, Itoh K, Yamamoto M, Mathis M, Orchard E, Shi R, McLarty J, Pruitt K, Zhang S, Kleiner-Hancock HE. Aggressive mammary carcinoma progression in Nrf2 knockout mice treated with 7,12-dimethylbenz[a]anthracene. BMC Cancer. 2010;10:540. https://doi.org/10.1186/1471-2407-10-540., DOI: 10.1186/1471-2407-10-540 49 10.1186/1471-2407-10-540 false true Reference 66478195 /api/reference/66478195 50. Zeng Z, Wang ZY, Li YK, Ye DM, Zeng J, Hu JL, Chen PF, Xiao J, Zou J, Li ZH. Nuclear factor erythroid 2 (NF-E2)-related factor 2 (Nrf2) in non-small cell lung cancer. Life Sci. 2020;254:117325. https://doi.org/10.1016/j.lfs.2020.117325., DOI: 10.1016/j.lfs.2020.117325 50 10.1016/j.lfs.2020.117325 false true Reference 66478196 /api/reference/66478196 51. Wu Q, Yao B, Li N, Ma L, Deng Y, Yang Y, Zeng C, Yang Z, Liu B. Nrf2 mediates redox adaptation in NOX4-overexpressed non-small cell lung cancer cells. Exp Cell Res. 2017;352:245–54. https://doi.org/10.1016/j.yexcr.2017.02.014., DOI: 10.1016/j.yexcr.2017.02.014 51 10.1016/j.yexcr.2017.02.014 false true Reference 66478197 /api/reference/66478197 52. Wang Q, Ma J, Lu Y, Zhang S, Huang J, Chen J, Bei JX, Yang K, Wu G, Huang K, Chen J, Xu S. CDK20 interacts with KEAP1 to activate NRF2 and promotes radiochemoresistance in lung cancer cells. Oncogene. 2017;36:5321–30. https://doi.org/10.1038/onc.2017.161., DOI: 10.1038/onc.2017.161 52 10.1038/onc.2017.161 false true Reference 66478198 /api/reference/66478198 53. Wang J, Liu Z, Hu T, Han L, Yu S, Yao Y, Ruan Z, Tian T, Huang T, Wang M, Jing L, Nan K, Liang X. Nrf2 promotes progression of non-small cell lung cancer through activating autophagy. Cell Cycle. 2017;16:1053–62. https://doi.org/10.1080/15384101.2017.1312224., DOI: 10.1080/15384101.2017.1312224 53 10.1080/15384101.2017.1312224 false true Reference 66478199 /api/reference/66478199 54. Tian Y, Liu Q, He X, Yuan X, Chen Y, Chu Q, Wu K. Emerging roles of Nrf2 signal in non-small cell lung cancer. J Hematol Oncol. 2016;9:14. https://doi.org/10.1186/s13045-016-0246-5., DOI: 10.1186/s13045-016-0246-5 54 10.1186/s13045-016-0246-5 false true Reference 66478200 /api/reference/66478200 55. Sparaneo A, Fabrizio FP, Muscarella LA. Nrf2 and Notch signaling in lung cancer: near the crossroad. Oxid Med Cell Longev. 2016;2016:7316492. https://doi.org/10.1155/2016/7316492., DOI: 10.1155/2016/7316492 55 10.1155/2016/7316492 false true Reference 66478201 /api/reference/66478201 56. Sanchez-Ortega M, Carrera AC, Garrido A. Role of NRF2 in Lung Cancer. Cells. 2021;10 https://doi.org/10.3390/cells10081879., DOI: 10.3390/cells10081879 56 10.3390/cells10081879 false true Reference 66478202 /api/reference/66478202 57. Namani A, Cui QQ, Wu Y, Wang H, Wang XJ, Tang X. NRF2-regulated metabolic gene signature as a prognostic biomarker in non-small cell lung cancer. Oncotarget. 2017;8:69847–62. https://doi.org/10.18632/oncotarget.19349., DOI: 10.18632/oncotarget.19349 57 10.18632/oncotarget.19349 false true Reference 66478203 /api/reference/66478203 58. Du W, Jiang Y, Zheng Z, Zhang Z, Chen N, Ma Z, Yao Z, Terada L, Liu Z. Feedback loop between p66(Shc) and Nrf2 promotes lung cancer progression. Cancer Lett. 2013;337:58–65. https://doi.org/10.1016/j.canlet.2013.05.016., DOI: 10.1016/j.canlet.2013.05.016 58 10.1016/j.canlet.2013.05.016 false true Reference 66478204 /api/reference/66478204 59. Wang Q, Xu L, Wang G, Chen L, Li C, Jiang X, Gao H, Yang B, Tian W. Prognostic and clinicopathological significance of NRF2 expression in non-small cell lung cancer: a meta-analysis. PLoS One. 2020;15:e0241241. https://doi.org/10.1371/journal.pone.0241241., DOI: 10.1371/journal.pone.0241241 59 10.1371/journal.pone.0241241 false true Reference 66478205 /api/reference/66478205 60. Singh A, Daemen A, Nickles D, Jeon SM, Foreman O, Sudini K, Gnad F, Lajoie S, Gour N, Mitzner W, Chatterjee S, Choi EJ, Ravishankar B, Rappaport A, Patil N, McCleland M, Johnson L, Acquaah-Mensah G, Gabrielson E, et al. NRF2 activation promotes aggressive lung cancer and associates with poor clinical outcomes. Clin Cancer Res. 2021;27:877–88. https://doi.org/10.1158/1078-0432.CCR-20-1985., DOI: 10.1158/1078-0432.CCR-20-1985 60 10.1158/1078-0432.CCR-20-1985 false true Reference 66478206 /api/reference/66478206 61. Gong M, Li Y, Ye X, Zhang L, Wang Z, Xu X, Shen Y, Zheng C. Loss-of-function mutations in KEAP1 drive lung cancer progression via KEAP1/NRF2 pathway activation. Cell Commun Signal. 2020;18:98. https://doi.org/10.1186/s12964-020-00568-z., DOI: 10.1186/s12964-020-00568-z 61 10.1186/s12964-020-00568-z false true Reference 66478207 /api/reference/66478207 62. Chen MJ, Lin PL, Wang L, Cheng YM, Chen CY, Lee H. Cytoplasmic, but not nuclear Nrf2 expression, is associated with inferior survival and relapse rate and response to platinum-based chemotherapy in non-small cell lung cancer. Thorac Cancer. 2020;11:1904–10. https://doi.org/10.1111/1759-7714.13479., DOI: 10.1111/1759-7714.13479 62 10.1111/1759-7714.13479 false true Reference 66478208 /api/reference/66478208 63. Sadeghi MR, Jeddi F, Soozangar N, Somi MH, Samadi N. The role of Nrf2-Keap1 axis in colorectal cancer, progression, and chemoresistance. Tumour Biol. 2017;39:1010428317705510. https://doi.org/10.1177/1010428317705510., DOI: 10.1177/1010428317705510 63 10.1177/1010428317705510 false true Reference 66478209 /api/reference/66478209 64. Razumovskaya AV, Silkina MO, Nikulin SV, Tonevitsky AG, Alekseev BY. Modulators of the Nrf2 signaling pathway enhance the cytotoxic effect of standard chemotherapeutic drugs on organoids of metastatic colorectal cancer. Bull Exp Biol Med. 2024;176:703–8. https://doi.org/10.1007/s10517-024-06093-0., DOI: 10.1007/s10517-024-06093-0 64 10.1007/s10517-024-06093-0 false true Reference 66478210 /api/reference/66478210 65. Hu M, Yuan L, Zhu J. The dual role of NRF2 in colorectal cancer: targeting NRF2 as a potential therapeutic approach. J Inflamm Res. 2024;17:5985–6004. https://doi.org/10.2147/JIR.S479794., DOI: 10.2147/JIR.S479794 65 10.2147/JIR.S479794 false true Reference 66478211 /api/reference/66478211 66. Tanaka Y, Hamada S, Matsumoto R, Taguchi K, Yamamoto M, Masamune A. Nrf2 expression in pancreatic stellate cells promotes progression of cancer. Am J Physiol Gastrointest Liver Physiol. 2021;321:G378–88. https://doi.org/10.1152/ajpgi.00120.2021., DOI: 10.1152/ajpgi.00120.2021 66 10.1152/ajpgi.00120.2021 false true Reference 66478212 /api/reference/66478212 67. Riazi-Tabrizi N, Khalaj-Kondori M, Safaei S, Amini M, Hassanian H, Maghsoudi M, Hasani S, Baradaran B. NRF2 suppression enhances the susceptibility of pancreatic cancer cells, miapaca-2 to paclitaxel. Mol Biotechnol. 2024;66:2441–54. https://doi.org/10.1007/s12033-023-00872-2., DOI: 10.1007/s12033-023-00872-2 67 10.1007/s12033-023-00872-2 false true Reference 66478213 /api/reference/66478213 68. Cykowiak M, Krajka-Kuzniak V. Role of Nrf2 in pancreatic cancer. Antioxidants. 2021;11 https://doi.org/10.3390/antiox11010098., DOI: 10.3390/antiox11010098 68 10.3390/antiox11010098 false true Reference 66478214 /api/reference/66478214 69. Ungvari Z, Bagi Z, Feher A, Recchia FA, Sonntag WE, Pearson K, de Cabo R, Csiszar A. Resveratrol confers endothelial protection via activation of the antioxidant transcription factor Nrf2. Am J Physiol Heart Circ Physiol. 2010;299:H18–24., DOI: 10.1152/ajpheart.00260.2010 69 10.1152/ajpheart.00260.2010 false true Reference 66478215 /api/reference/66478215 70. Rubiolo JA, Mithieux G, Vega FV. Resveratrol protects primary rat hepatocytes against oxidative stress damage: Activation of the Nrf2 transcription factor and augmented activities of antioxidant enzymes. Eur J Pharmacol. 2008;591:66–72. https://doi.org/10.1016/j.ejphar.2008.06.067., DOI: 10.1016/j.ejphar.2008.06.067 70 10.1016/j.ejphar.2008.06.067 false true Reference 66478216 /api/reference/66478216 71. Kode A, Rajendrasozhan S, Caito S, Yang SR, Megson IL, Rahman I. Resveratrol induces glutathione synthesis by activation of Nrf2 and protects against cigarette smoke-mediated oxidative stress in human lung epithelial cells. Am J Physiol Lung Cell Mol Physiol. 2008;294:L478–88., DOI: 10.1152/ajplung.00361.2007 71 10.1152/ajplung.00361.2007 false true Reference 66478217 /api/reference/66478217 72. Thimmulappa RK, Mai KH, Srisuma S, Kensler TW, Yamamoto M, Biswal S. Identification of Nrf2-regulated genes induced by the chemopreventive agent sulforaphane by oligonucleotide microarray. Cancer Res. 2002;62:5196–203. 72 false true Reference 66478218 /api/reference/66478218 73. Shin JW, Chun KS, Kim DH, Kim SJ, Kim SH, Cho NC, Na HK, Surh YJ. Curcumin induces stabilization of Nrf2 protein through Keap1 cysteine modification. Biochem Pharmacol. 2020;173:113820. https://doi.org/10.1016/j.bcp.2020.113820., DOI: 10.1016/j.bcp.2020.113820 73 10.1016/j.bcp.2020.113820 false true Reference 66478219 /api/reference/66478219 74. Garufi A, Baldari S, Pettinari R, Gilardini Montani MS, D'Orazi V, Pistritto G, Crispini A, Giorno E, Toietta G, Marchetti F, Cirone M, D’Orazi G. A ruthenium(II)-curcumin compound modulates NRF2 expression balancing the cancer cell death/survival outcome according to p53 status. J Exp Clin Cancer Res. 2020;39:122. https://doi.org/10.1186/s13046-020-01628-5., DOI: 10.1186/s13046-020-01628-5 74 10.1186/s13046-020-01628-5 false true /api/publication/36202274 Ungvari Zoltan et al. NRF2 pathway activation predicts poor prognosis in lung cancer: a cautionary note on antioxidant interventions. (2026) GEROSCIENCE: OFFICIAL JOURNAL OF THE AMERICAN AGING ASSOCIATION (AGE) 2509-2715 2509-2723 48 1 1345-1356<div class="JournalArticle Publication long-list"> <div class="authors"> <img title="Forrásközlemény" style="float: left" src="/frontend/resources/grid/publication-core-icon.png"> <img title="Idézőközlemény" style="float: left" src="/frontend/resources/grid/publication-citation-icon.png"> <div class="autype autype0"> <span class="author-name" mtid="10043602"><a href="/gui2/?type=authors&mode=browse&sel=10043602" target="_blank">Ungvari Zoltan (<span class="authorship-author-name">Ungvári Zoltán István</span> <span class="authorAux-mtmt"> Orvostudomány, megelőző orvostan, népegészségta...</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/Megelőző Orvostani és Népegészségtani Intézet </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10045338"><a href="/gui2/?type=authors&mode=browse&sel=10045338" target="_blank">Menyhart Otília^* (<span class="authorship-author-name">Menyhárt Otília</span> <span class="authorAux-mtmt"> Onkológia</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/Bioinformatika Tanszék; <span title="HUN-REN Természettudományi Kutatóközpont">HRN TTK</span>/<span title="Molekuláris Élettudományi Intézet">MÉI</span>/Onkológiai Biomarker Kutatócsoport (Lendület)</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10089009"><a href="/gui2/?type=authors&mode=browse&sel=10089009" target="_blank">Lehoczki Andrea^* ✉ (<span class="authorship-author-name">Lehoczki Andrea Marianna</span> <span class="authorAux-mtmt"> hematológia, belgyógyászat</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/Megelőző Orvostani és Népegészségtani Intézet ; <span title="Semmelweis Egyetem">SE</span>/Doktori Iskola</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10058020"><a href="/gui2/?type=authors&mode=browse&sel=10058020" target="_blank">Fekete Monika (<span class="authorship-author-name">Fekete Mónika</span> <span class="authorAux-mtmt"> Népegészségtan</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/Megelőző Orvostani és Népegészségtani Intézet </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10035785"><a href="/gui2/?type=authors&mode=browse&sel=10035785" target="_blank">Fazekas-Pongor Vince (<span class="authorship-author-name">Fazekas-Pongor Vince</span> <span class="authorAux-mtmt"> népegészségtan</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/Megelőző Orvostani és Népegészségtani Intézet </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Ocana Alberto </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10081446"><a href="/gui2/?type=authors&mode=browse&sel=10081446" target="_blank">Varga Peter (<span class="authorship-author-name">Varga Péter</span> <span class="authorAux-mtmt"> foglalkozás-orvostan</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/Megelőző Orvostani és Népegészségtani Intézet </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10000109"><a href="/gui2/?type=authors&mode=browse&sel=10000109" target="_blank">Győrffy Balázs (<span class="authorship-author-name">Győrffy Balázs</span> <span class="authorAux-mtmt"> Onkológia</span>) </a> </span> <span class="author-affil"><span title="HUN-REN Természettudományi Kutatóközpont">HRN TTK</span>/<span title="Molekuláris Élettudományi Intézet">MÉI</span>/Onkológiai Biomarker Kutatócsoport (Lendület); <span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/Bioinformatika Tanszék; <span title="Pécsi Tudományegyetem">PTE</span>/<span title="Általános Orvostudományi Kar">ÁOK</span>/Biofizikai Intézet</span> </div> </div> <div class="title"><a href="/gui2/?mode=browse&params=publication;36202274" target="_blank">NRF2 pathway activation predicts poor prognosis in lung cancer: a cautionary note on antioxidant interventions</a></div> <div> <span class="journal-title">GEROSCIENCE: OFFICIAL JOURNAL OF THE AMERICAN AGING ASSOCIATION (AGE)</span> <span class="journal-issn">(<a target="_blank" href="https://portal.issn.org/resource/ISSN/2509-2715">2509-2715</a> <a target="_blank" href="https://portal.issn.org/resource/ISSN/2509-2723">2509-2723</a>)</span>: <span class="journal-volume">48</span> <span class="journal-issue">1</span> <span class="page"> pp 1345-1356 </span> <span class="year">(2026)</span> </div> <div class="pub-footer"> <span class="language" xmlns="http://www.w3.org/1999/html">Nyelv: Angol | </span> <span class="identifiers"> <span class="id identifier oa_GOLD" title=" Gold "> <a style="color:blue" title="10.1007/s11357-025-01736-0" target="_blank" href="https://doi.org/10.1007/s11357-025-01736-0"> DOI </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="001511729300001" target="_blank" href="https://www.webofscience.com/wos/woscc/full-record/001511729300001"> WoS </a> </span> <span class="id identifier oa_GOLD" title=" Gold "> <a style="color:black" title="246670" target="_blank" href="https://real.mtak.hu/246670"> REAL </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="105008382211" target="_blank" href="http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-105008382211"> Scopus </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="40537696" target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=40537696&dopt=Abstract"> PubMed </a> </span> <span class="id identifier oa_NONE" title=" Nincs "> <a style="color:blue" title="https://www.scopus.com/inward/record.uri?eid=2-s2.0-105008382211&doi=10.1007%2Fs11357-025-01736-0&partnerID=40&md5=0634bfaa6d6206f66167818ffa7c889c" target="_blank" href="https://www.scopus.com/inward/record.uri?eid=2-s2.0-105008382211&doi=10.1007%2Fs11357-025-01736-0&partnerID=40&md5=0634bfaa6d6206f66167818ffa7c889c"> Egyéb URL </a> </span> <span class="id identifier oa_NONE" title=" Nincs "> <a style="color:blue" title="https://www.scopus.com/pages/publications/105008382211?origin=resultslist" target="_blank" href="https://www.scopus.com/pages/publications/105008382211?origin=resultslist"> Egyéb URL </a> </span> </span> <OnlyViewableByAuthor><div class="ratings"> <div class="journal-subject">Folyóirat szakterülete: Scopus - Complementary and Alternative Medicine&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;D1</div> <div class="journal-subject">Folyóirat szakterülete: Scopus - Geriatrics and Gerontology&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;D1</div> <div class="journal-subject">Folyóirat szakterülete: Scopus - Veterinary (miscellaneous)&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;D1</div> <div class="journal-subject">Folyóirat szakterülete: Scopus - Aging&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;Q1</div> <div class="journal-subject">Folyóirat szakterülete: Scopus - Cardiology and Cardiovascular Medicine&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;Q1</div> </div></OnlyViewableByAuthor> <div class="publication-citation" style="margin-left: 0.5cm;"> <span title="Nyilvános idézőközlemények összesen, említések nélkül" class="citingPub-count">Nyilvános idéző összesen: 6</span> | Független: 4 | Függő: 2 | Nem jelölt: 0 | WoS jelölt: 2 | Scopus jelölt:&nbsp;1 | WoS/Scopus jelölt:&nbsp;3 | DOI jelölt:&nbsp;4 </div> <div class="publication-citation"> <a target="_blank" href="/api/publication?cond=citations.related;eq;36202274&sort=publishedYear,desc&sort=title"> Idézett közlemények száma: 7 </a> </div> <div class="mtid"><span class="long-pub-mtid">Közlemény: 36202274</span> | <span class="status-data status-ADMIN_APPROVED"> Admin láttamozott </span> Forrás Idéző | <span class="type-subtype">Folyóiratcikk ( Szakcikk ) </span> | <span class="pub-category">Tudományos</span> | <span class="publication-sourceOfData">WOS TAGGED</span> </div> <div class="funder"> (FK147194), Nemzeti Gyógyszerkutatási és Fejlesztési Laboratórium (PharmaLab)(RRF-2.3.1-21-2022-00015) Támogató: NKFIH, (TKP2021-NKTA-47), Nemzeti Kardiovaszkuláris Laboratórium(RRF-2.3.1-21-2022-00003) Támogató: NKFIH, (TKCS-2021/32), (EKÖP-2024-9) </div> <div class="lastModified">Utolsó módosítás: 2026.05.18. 16:41 Sonnevend Kinga (SE_AOK_Adm5_Élet_kutcsop, admin) </div> <pre class="comment" style="margin-top: 0; margin-bottom: 0;"><u>Megjegyzés</u>: * Megosztott szerzőség</pre> </div></div>